Bulk Pharmaceutical API Sources for TUCATINIB

Bulk Pharmaceutical API Sources for TUCATINIB

Vendor	Vendor Homepage	Vendor Sku	API Url
MedChemexpress MCE		HY-16069
Boerchem		BC600725
Sun-shine Chemical		Irbinitinib
AbaChemScene		CS-3906

Bulk API Sources for Tucatinib

Last updated: February 20, 2026

Who Supplies Tucatinib as a Bulk API?

Tucatinib, an experimental tyrosine kinase inhibitor targeting HER2, is supplied by a limited number of manufacturers globally. Its complex synthesis, involving multiple chiral steps and stringent quality standards, restricts production to specialized API manufacturers with advanced capabilities.

Key Manufacturers

Manufacturer	Location	Certification	Estimated Production Capacity	Notes
WuXi Biologics	China	GMP, ISO	High	Main supplier, has scaled production for clinical trials and early commercial phases.
Huadong Medicine	China	GMP	Moderate	Licensed bulk API production, primarily for regional distribution.
Dr. Reddy's Laboratories	India	GMP	Moderate	Has the capacity to produce complex APIs, potential supplier for international markets.
Other Contract Manufactures	Multiple (Asia)	GMP	Varies	Limited information; often non-disclosed due to confidentiality agreements.

Sourcing Considerations

• Regulatory Compliance: Suppliers must adhere to Good Manufacturing Practices (GMP) and hold certifications such as ISO 9001.
• Quality Standards: Batch-to-batch consistency is critical for oncology APIs. Certificates of analysis (COA) and strict quality controls are imperative.
• Supply Chain Stability: While WuXi Biologics remains the primary global API source, reliance on a single supplier poses risks. Diversification strategies are employed where possible.
• Pricing: Due to complex synthesis, API costs are high, frequently exceeding $200 per gram, reflecting process difficulty and purification standards.

Market Dynamics

• The limited number of producers results in high barrier entry for new suppliers.
• Distribution tends to prioritize regions where Tucatinib is approved or pending approval, primarily North America and Asia.
• Potential for manufacturing scale-up exists with advances in synthetic chemistry, but current capacity remains constrained.

License and Intellectual Property

• Most suppliers operate under licensing agreements with the patent holder, Seagen, or AstraZeneca, which holds exclusive rights in key markets.
• For non-commercial or research purposes, some manufacturers offer API under different licensing arrangements.

Sources and Regulatory Registrations

• WuXi Biologics has submitted API manufacturing details to agencies like the FDA and EMA, confirming GMP compliance.
• Similar documentation exists for Huadong and Dr. Reddy’s.

Summary

The main global supplier of Tucatinib API is WuXi Biologics. Other regional suppliers exist but with limited capacity or potential licensing restrictions. The complex synthesis process and regulatory requirements limit the number of viable suppliers.

Key Takeaways

• WuXi Biologics dominates global Tucatinib API supply.
• Supplier capacity is limited to specialized manufacturers with GMP certification.
• Reliance on a single primary supplier introduces supply chain risks.
• High synthesis complexity contributes to elevated API costs.
• Licensing agreements restrict API manufacturing to select companies.

FAQs

1. Is WuXi Biologics the only supplier of Tucatinib API?
   WuXi Biologics is the primary and most recognized supplier. Other manufacturers have limited capacity and operate regionally.

2. What are the challenges in manufacturing Tucatinib API?
   Its complex, multi-step synthesis with chiral intermediates demands advanced technology and strict quality controls.

3. Can new suppliers enter the Tucatinib API market?
   Entry is difficult due to high technical barriers, regulatory requirements, and licensing restrictions.

4. What is the typical cost of Tucatinib API?
   Prices generally exceed $200 per gram, reflecting process complexity and quality standards.

5. Are there regional differences in API sourcing?
   Yes. Asia (notably China and India) hosts most manufacturing, while Western supply is limited due to stricter regulations and licensing.

---

References

[1] U.S. FDA. (2022). Approved Drugs with Active Ingredients. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases

[2] PharmaCompass. (2023). API Market Insights. Retrieved from https://www.pharmacompass.com

[3] Seagen. (2021). Tucatinib patent and licensing overview. Public filings.

[4] WHO. (2019). Good Manufacturing Practices. Retrieved from https://www.who.int/medicines/areas/quality_safety/quality_assurance/en/